Traders should monitor the upcoming APEX Part B 16-week induction data in 2Q 2026, which will be critical for confirming efficacy and supporting Phase 3 initiation. Positive results could further drive upside given the high unmet need for infrequently dosed AD therapies.
Price Chart
Executive Summary
Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX trial for zumilokibart (APG777), an anti-IL-13 antibody in moderate-to-severe atopic dermatitis. The drug showed durable and deepening responses with every 3- and 6-month dosing, supporting its potential as a best-in-class therapy with infrequent dosing. Phase 3 trials are expected to begin in the second half of 2026, with a potential 2029 commercial launch.
Key Facts
- Zumilokibart demonstrated 75% and 85% maintenance of EASI-75 response at 52 weeks with every 3- and 6-month dosing, respectively.
- vIGA 0/1 response was maintained in 86% (3-month) and 78% (6-month) of Week 16 responders.
- Deepening of response observed across all lesional and itch endpoints in the full treated population, not just initial responders.
- Drug was well tolerated with a safety profile consistent with class; most common TEAEs: noninfective conjunctivitis, URTI, nasopharyngitis.
- Phase 3 trials expected to initiate in 2H 2026, with potential commercial launch in 2029.
Financial Impact
No direct financial figures reported, but successful Phase 2 data de-risks development and increases probability of regulatory approval and commercial success.
Risk Factors
- Phase 3 trials have not yet started; clinical success in Phase 2 does not guarantee Phase 3 outcomes.
- Competition from existing and emerging IL-13/IL-4 inhibitors (e.g., dupilumab, tralokinumab) with established market presence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access